Literature DB >> 8576840

Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.

Y Merlé1, F Mentré.   

Abstract

In this paper 3 criteria to design experiments for Bayesian estimation of the parameters of nonlinear models with respect to their parameters, when a prior distribution is available, are presented: the determinant of the Bayesian information matrix, the determinant of the pre-posterior covariance matrix, and the expected information provided by an experiment. A procedure to simplify the computation of these criteria is proposed in the case of continuous prior distributions and is compared with the criterion obtained from a linearization of the model about the mean of the prior distribution for the parameters. This procedure is applied to two models commonly encountered in the area of pharmacokinetics and pharmacodynamics: the one-compartment open model with bolus intravenous single-dose injection and the Emax model. They both involve two parameters. Additive as well as multiplicative gaussian measurement errors are considered with normal prior distributions. Various combinations of the variances of the prior distribution and of the measurement error are studied. Our attention is restricted to designs with limited numbers of measurements (1 or 2 measurements). This situation often occurs in practice when Bayesian estimation is performed. The optimal Bayesian designs that result vary with the variances of the parameter distribution and with the measurement error. The two-point optimal designs sometimes differ from the D-optimal designs for the mean of the prior distribution and may consist of replicating measurements. For the studied cases, the determinant of the Bayesian information matrix and its linearized form lead to the same optimal designs. In some cases, the pre-posterior covariance matrix can be far from its lower bound, namely, the inverse of the Bayesian information matrix, especially for the Emax model and a multiplicative measurement error. The expected information provided by the experiment and the determinant of the pre-posterior covariance matrix generally lead to the same designs except for the Emax model and the multiplicative measurement error. Results show that these criteria can be easily computed and that they could be incorporated in modules for designing experiments.

Mesh:

Year:  1995        PMID: 8576840     DOI: 10.1007/bf02353788

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  8 in total

1.  APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics.

Authors:  A Iliadis; A C Brown; M L Huggins
Journal:  Comput Methods Programs Biomed       Date:  1992-08       Impact factor: 5.428

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  An application of population pharmacokinetics to the clinical use of cyclosporine in bone marrow transplant patients.

Authors:  F Mentré; A Mallet; J L Steimer; F Lokiec
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

Review 4.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

5.  Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake.

Authors:  Y Merlé; F Mentré; A Mallet; A H Aurengo
Journal:  Stat Med       Date:  1994-01-30       Impact factor: 2.373

6.  The use of prior distributions in the design of experiments for parameter estimation in non-linear situations: multiresponse case.

Authors:  N R Draper; W G Hunter
Journal:  Biometrika       Date:  1967-12       Impact factor: 2.445

7.  Computer-assisted individual estimation of radioiodine thyroid uptake in Grave's disease.

Authors:  Y Merlé; F Mentré; A Mallet; A Aurengo
Journal:  Comput Methods Programs Biomed       Date:  1993-05       Impact factor: 5.428

8.  Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.

Authors:  Y Hashimoto; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1991-06
  8 in total
  11 in total

1.  Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.

Authors:  Y Merlé; F Mentré
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

2.  A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.

Authors:  Thu Thuy Nguyen; Henri Bénech; Alain Pruvost; Natacha Lenuzza
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

3.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

4.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

5.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

6.  Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹.

Authors:  David S Bayard; Michael Neely
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-12-01       Impact factor: 2.745

7.  Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.

Authors:  John Carl Panetta; Mark Wilkinson; Ching-Hon Pui; Mary V Relling
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

8.  Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.

Authors:  F P Combes; S Retout; N Frey; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-09

9.  Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.

Authors:  T H T Nguyen; J Guedj; J Yu; M Levi; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-17

10.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.